Replies to post #445698 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Hi meirluc.
Allow me to respond.
The statement in JTM was probably more or less accurate at the time it was written: at least several months before it was published. Maybe getting on for a year..
Remember they had all the shenanigans with the "top journal" (or journals) faffing about asking for amendments and rewrites (at least that's my supposition), before they decided to pay and get it put out in a timely fashion by JTM.
By the time they got to the SNO update, they wouldn't and didn't repeat the statement (as far as I'm aware). Because by then, they would have known it was no longer accurate.
As to why, the superior survival of late entrants occurred, I like 3(a) the most.The other factors you mention may have played their part, but 3(a) was probably the most significant, in my opinion.

Regards.

[flipper44]

3A and 3C. We’ve talked about 3C at length on this board, so no reason to go back explaining that. Safe to say, there is a reason Dr. Ashkan is very excited. There is a reason why Jerry Jasinowsi stated the latter (blinded) data look particularly good. There is a reason Dr. Liau does not want anyone subjected to a placebo control arm plus Temodar. There is a reason Dr. Stupp readily admits Temodar does not work in unmethylated. There is a reason Merck is winding down it’s Temodar assistance program. There is a reason Linda Powers states this is likely the last concurrent (now hybrid) control trial possible for DCVax-l as the experimental arm. There is a reason the new endpoints will help transition future trial indications away from placebo controlled trials. There is a reason DCVax-l is the control in the combination trial. There is a reason LL can tell if a patient’s immune system needs a booster. There are reasons for everything. That said, where’s the Journal???

[sentiment_stocks]

To be clear... I don't think the trial was tipped to only enroll treatment patients over the summer of 2015, or even after August 2015. I don't think that because those who speak for the company unequivocally do not believe that to be the case, IMO.

It could be A, if the tipping point to treatment occurred in the final 100 (as opposed to having been evenly spread out over the trial). And C... Improvements in surgery, via ALA and perhaps other techniques could also account for this.

Could it perhaps have been due to more methylated were enrolled in the later part of the trial, while more unmethylated in the earlier part of the trial?

For my part, I don't believe TFF was used in the L P3. Perhaps they plan on implementing it upon or after commercialization. I look forward to getting some solid answers one of these dang days!

:)